Aptevo Therapeutics Inc.
Income Statement
| Line Item | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | FY2015 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $3.1M | $12.3M | $4.3M | $32.4M | $23.1M | $14.7M | $10.0M | $33.6M |
| Cost of Revenue | — | — | — | $19.9M | $11.2M | $5.0M | $12.5M | $16.9M |
| Gross Profit | — | — | — | $12.5M | $11.9M | $9.6M | $-2.5M | $16.7M |
| Gross Margin | — | — | — | 38.5% | 51.4% | 65.8% | -24.9% | 49.6% |
| Operating Expenses | ||||||||
| Research & Development | $17.9M | $19.0M | $17.9M | $24.8M | $35.4M | $29.0M | $29.1M | $34.7M |
| SG&A Expense | $13.9M | $14.7M | $14.0M | $25.3M | $28.1M | $34.6M | $36.2M | $43.0M |
| Operating Income | $-28.6M | $-21.4M | $-27.5M | $-41.0M | $-51.7M | $-53.9M | $-138.8M | $-61.1M |
| Operating Margin | -919.7% | -174.1% | -638.1% | -126.3% | -224.0% | -368.1% | -1,389.8% | -181.8% |
| Interest Expense | — | — | — | — | — | — | — | — |
| Pretax Income | $7.0M | $-29.4M | $-30.9M | $-43.1M | $-53.7M | $-55.9M | $-139.6M | $-61.3M |
| Income Tax Expense | — | — | — | — | — | $-23.3M | $-19.7M | $-2.0M |
| Net Income | $8.0M | $-28.5M | $-17.8M | $-40.4M | $-53.7M | $7.0M | $-112.4M | $-59.3M |
| Net Margin | 257.8% | -231.5% | -411.9% | -124.7% | -232.8% | 47.6% | -1,125.8% | -176.5% |
| EPS (Basic) | $0.79 | $-3.04 | $-2.62 | $-6.93 | $-1.20 | $0.17 | $-2.78 | $-1.47 |
| EPS (Diluted) | $0.79 | $-3.04 | $-2.62 | $-6.93 | $-1.20 | $0.17 | $-2.78 | $-1.47 |
| Shares Outstanding (Basic) | 10.2M | 9.4M | 8.8M | 6.5M | 45.6M | 43.2M | 40.5M | 0 |
| Shares Outstanding (Diluted) | 10.2M | 9.4M | 8.8M | 6.5M | 45.6M | 43.2M | 40.5M | 0 |
| Dividends Per Share | — | — | — | — | — | — | — | — |